Robert W. Baird Increases ICON Public (NASDAQ:ICLR) Price Target to $376.00

ICON Public (NASDAQ:ICLR) had its price objective boosted by Robert W. Baird from $367.00 to $376.00 in a report released on Monday, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A number of other equities research analysts have also weighed in on the stock. Mizuho reiterated a buy rating and set a $346.00 target price on shares of ICON Public in a research note on Thursday, April 4th. William Blair reiterated an outperform rating on shares of ICON Public in a research note on Friday, May 31st. The Goldman Sachs Group started coverage on shares of ICON Public in a research note on Thursday, June 6th. They set a buy rating and a $370.00 target price for the company. TD Cowen upped their price objective on ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a research note on Friday, May 31st. Finally, Evercore ISI reduced their price objective on ICON Public from $350.00 to $330.00 and set an outperform rating for the company in a research note on Friday, April 26th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, ICON Public has an average rating of Moderate Buy and a consensus price target of $346.20.

ICON Public Stock Performance

ICLR stock opened at $328.65 on Monday. The stock has a market capitalization of $27.11 billion, a PE ratio of 39.98, a price-to-earnings-growth ratio of 1.43 and a beta of 1.23. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. The stock’s 50 day simple moving average is $317.57 and its 200 day simple moving average is $304.28. ICON Public has a 12-month low of $221.20 and a 12-month high of $344.77.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, April 24th. The medical research company reported $3.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.30 by $0.08. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.09 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. As a group, research analysts forecast that ICON Public will post 14.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bruce G. Allen Investments LLC bought a new position in ICON Public in the 4th quarter worth $25,000. Riverview Trust Co bought a new position in shares of ICON Public during the 1st quarter valued at about $31,000. Livelsberger Financial Advisory bought a new position in shares of ICON Public during the 4th quarter valued at about $29,000. Pinnacle Bancorp Inc. boosted its holdings in shares of ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares during the last quarter. Finally, GAMMA Investing LLC bought a new position in shares of ICON Public during the 4th quarter valued at about $37,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.